© BusinessWire
13.08.2024
INDV
LISTED
NASDAQ
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Indivior PLC (INDV)
News Preview
Law Offices of Howard G. Smith reminds investors of the upcoming October 1, 2024 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”).
Investors suffering losse...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.08.2024
ZEAL
LISTED
CPH
Zealand Pharma conference call on August 15 at 2pm CET (8am ET) to present first half 2024 financial results
News Preview
Press Release – No. 8 / 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
12.08.2024
BLUE
LISTED
NASDAQ
bluebird bio Announces Second Quarter 2024 Results Call Date
News Preview
bluebird bio, Inc. (Nasdaq: BLUE) announced today that it will host a conference call to discuss second quarter 2024 results and business updates on August 14, at 8:00 a.m. ET.
To participate in the conference call, please dial +1 (800) 715-9871 (U.S. and Canada) and ask to be joined into the bluebird call or provide the Conference ID 2776050....
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
11.08.2024
INDV
LISTED
NASDAQ
INDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
News Preview
Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Indivior PLC (“Indivior” or “the Company”) (NASDAQ: INDV) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleged viola...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© BusinessWire
09.08.2024
INDV
LISTED
NASDAQ
Indivior PLC Investor Notice: Robbins LLP Reminds Stockholders of the INDV Class Action Lawsuit
News Preview
Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired Indivior PLC (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024. Indivior is a global pharmaceutical company that develops, manufactures, and markets drugs to treat opioid use disorders...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience Reports Second Quarter 2024 Financial Results and Recent Highlights
News Preview
Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024 Advancement of clinical and regulatory steps enable the expected initiation of Phase 2 obesity clinical trial for nimacimab peripheral CB1 inhibitor in Q3 2024...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
DFTX
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Pricing of Public Offering
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced the pricing of an underwritten public offering of 9,285,511 common shares, without par value, at a public offering price of $7.00 per common share,...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
AMRX
LISTED
NASDAQ
Amneal Reports Second Quarter 2024 Financial Results
News Preview
Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) announced its results today for the second quarter ended June 30, 2024.
“Amneal achieved strong revenues and adjusted EBITDA in the second quarter, and we are pleased to raise full year 2024 guidance driven by broad-based growth across our business. Amneal is a diversified a...
Themefolio
Profiler
Peergroup
© BusinessWire
09.08.2024
DFTX
LISTED
NASDAQ
Mind Medicine (MindMed) Inc. Announces Proposed Public Offering
News Preview
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it intends to offer and sell, subject to market conditions, common shares and, to certain investors, pre-funded warrants to purchase common sh...
Themefolio
Profiler
Peergroup
© Globe Newswire
09.08.2024
LEGN
LISTED
NASDAQ
Legend Biotech Reports Second Quarter 2024 Results and Recent Highlights
News Preview
SOMERSET, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today reported its second quarter 2024 unaudited financial results and key corporate highlights....
Themefolio
Profiler
Peergroup
© PR Newswire
09.08.2024
RAY B
LISTED
STO
Invitation to presentation of RaySearch's interim report for the second quarter of 2024
News Preview
STOCKHOLM, Aug. 9, 2024 /PRNewswire/ -- Analysts, investors, and the media are invited to a presentation of RaySearch's interim report for the second quarter of 2024 on August 16, 2024, at 10.00 am CEST. The report will be published on August 16, 2024, at 07.45 am and will be available together with presentation slides on raysearchlabs.com. Johan...
Themefolio
Profiler
Peergroup
© EQS Newswire
09.08.2024
EUZ
LISTED
XETR
Eckert & Ziegler Continues Sales and Earnings Growth in the First Half of 2024
News Preview
2nd Quarter 2024:
Sales: € 77.8 Mio. million (PY: € 60.1 million)
EBIT before special items: € 17.5 million (PY: € 12.0 million)
Net income: € 9.5 million (PY: € 6.2 million)
1st Half Year 2024:
Sales: € 145,4 million (PY: € 118.0 million)
EBIT before special items: € 32.5 million (PY: € 22.6 million)
Net income: € 18.0 million (PY: € 10.9 mi......
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© EQS Newswire
09.08.2024
EUZ
LISTED
XETR
Eckert & Ziegler setzt Umsatz- und Gewinnwachstum im ersten Halbjahr 2024 fort
News Preview
2. Quartal 2024:
Umsatz: 77,8 Mio. € (VJ: 60,1 Mio. €)
EBIT vor Sondereinflüssen: 17,5 Mio. € (VJ: 12,0 Mio. €)
Nettogewinn: 9,5 Mio. € (VJ: 6,2 Mio. €)
1. Halbjahr 2024:
Umsatz: 145,4 Mio. € (VJ: 118,0 Mio. €)
EBIT vor Sondereinflüssen: 32,5 Mio. € (VJ: 22,6 Mio. €)
Nettogewinn: 18,0 Mio. € (VJ: 10,9 Mio. €)
Jahresprognose 2024:
Umsatz von ......
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
SKYE
LISTED
NASDAQ
Skye Bioscience, Inc. (SKYE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Skye Bioscience, Inc. (“Skye” or “the Company”) (NASDAQ: SKYE). Investors who purchased Skye securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/SKYE....
Themefolio
Profiler
Peergroup
© BusinessWire
08.08.2024
INDV
LISTED
NASDAQ
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Indivior PLC (INDV) Investors
News Preview
Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, announces that a class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Indivior PLC (“Indivior” or the “Company”) (NASDAQ: INDV) securities between February 22, 2024 and July 8, 2024, inclusive (the “Class Period”). Ind...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
RXRX
LISTED
NASDAQ
CORRECTION - Recursion Provides Business Updates and Reports Second Quarter 2024 Financial Results
News Preview
SALT LAKE CITY, Aug. 08, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Recursion (Nasdaq: RXRX), please note that in the first bullet under "Additional Corporate Updates", the company's conference call should have been mentioned as having already taken place earlier this morning, rather than coming up later...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
1SXP
LISTED
XETR
SCHOTT Pharma richtet Klimaschutzmaßnahmen an den Anforderungen des Pariser Abkommens aus
News Preview
SCHOTT Pharma richtet Klimaschutzmaßnahmen an den Anforderungen des Pariser Abkommens aus
8. August 2024, Deutschland, Mainz
SCHOTT Pharma bekennt sich zu seiner Verantwortung, Emissionen zu reduzieren, um die globale Erwärmung auf 1,5°C zu begrenzen.
Die unabhängige Science Based Targets Initiative (SBTi) hat die Klimaschutz-Roadmap und Ziele ......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
1SXP
LISTED
XETR
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
News Preview
SCHOTT Pharma reinforces commitment to align its climate actions to the requirements of the Paris Agreement
August 8, 2024, Germany, Mainz
SCHOTT Pharma is fully committed to take responsibility for emission reduction to support limitation of global warming to 1.5°C.
The independent Science Based Targets initiative (SBTi) has validated the clima......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
GMAB
LISTED
CPH
Genmab Announces Financial Results for the First Half of 2024
News Preview
August 8, 2024 Copenhagen, Denmark; Interim Report for the First Six Months Ended June 30, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
GMAB
LISTED
CPH
Genmab Updates 2024 Financial Guidance
News Preview
Company Announcement...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
SOBI
LISTED
STO
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
News Preview
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favourable safety, consistent with es...
Themefolio
Profiler
Peergroup
© PR Newswire
08.08.2024
SOBI
LISTED
STO
Sobi and Apellis announce positive topline results from phase 3 VALIANT study of pegcetacoplan in C3G and primary IC-MPGN
News Preview
Met the primary endpoint, achieving statistically significant 68% (p<0.0001) reduction in proteinuria compared to placebo in a broad study populationPositive results consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneysDemonstrated favourable safety, consistent with es...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
AUTL
LISTED
NASDAQ
Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
News Preview
Autolus Therapeutics Reports Second Quarter 2024 Financial Results
and Business Updates...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
ORNBV
LISTED
HEL
Orion Group Half-Year Financial Report January–June 2024
News Preview
ORION CORPORATION HALF-YEAR FINANCIAL REPORT 1–6/2024 8 AUGUST 2024 at 12:00 EEST...
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
EVT
LISTED
XETR
Evotec announces progress in strategic neuroscience partnership with Bristol Myers Squibb
News Preview
Key scientific achievement advances the joint neuroscience pipeline and earns a payment of US$ 25 m to Evotec to progress further research
Hamburg, Germany, 08 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) today announced progress within the Company’s strategic partnership wit......
Themefolio
Profiler
Peergroup
© EQS Newswire
08.08.2024
EVT
LISTED
XETR
Evotec verkündet Fortschritt in strategischer Neurologie-Partnerschaft mit Bristol Myers Squibb
News Preview
Wichtiger wissenschaftlicher Fortschritt bringt die gemeinsame Neurologie - Pipeline voran und löst eine Zahlung von 25 Mio. US$ an Evotec aus, um die weitere Forschung voranzutreiben
Hamburg, 08. August 2024:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) gab heute einen Fortschritt in ......
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
ORNBV
LISTED
HEL
Orion Corporation’s financial reporting and Annual General Meeting in 2025
News Preview
ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR8 AUGUST 2024 at 9.45 EEST ...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
RXRX
LISTED
NASDAQ
Recursion updates L(earnings) call on August 8th to 8:30 am ET / 6:30 am MT
News Preview
Salt Lake City, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, will provide business updates and report its Q2 2024 financial results on Thursday, August 8, 2024, before the opening of the financial markets. Recursion will host a L(earnings) C...
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
EVT
LISTED
XETR
Evotec SE berichtet Ergebnisse für das erste Halbjahr 2024 am 14. August 2024
News Preview
Hamburg, 07. August 2024:
Evotec SE (Frankfurter Wertpapierbörse: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) veröffentlicht am Mittwoch, 14. August 2024, die Ergebnisse für das erste Halbjahr 2024.
In einer Telefonkonferenz in englischer Sprache werden die Ergebnisse und Schwerpunkte aus dem Berichtszeitraum näher erläutert. Außerdem wird ......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
EVT
LISTED
XETR
Evotec SE reports first half-year 2024 results on 14 August 2024
News Preview
Hamburg, Germany, 07 August 2024:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) will announce its financial results for the first half-year of 2024 on Wednesday, 14 August 2024.
The Company is going to hold a conference call to discuss the results as well as provide an update on its performance. The con......
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
CELC
LISTED
NASDAQ
Celcuity Inc. Schedules Release of Second Quarter 2024 Financial Results and Webcast/Conference Call
News Preview
MINNEAPOLIS, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced that it will release its financial results for the second quarter 2024 after the market closes on Wednesday, August 14, 2024. Management will host a webcast/te...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.08.2024
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Reports Second-Quarter 2024 Financial Results and Provides Corporate Updates
News Preview
CONSHOHOCKEN, Pa., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2024 financial results and provides corporate updates....
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
FYB
LISTED
XETR
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
News Preview
Press Release // August 7, 2024
Formycon invites to conference call on 2024 half-year results and announces participation in international investor conferences
Planegg-Martinsried, Germany – Formycon AG (FWB: FYB) today announced details for the financial and earnings conference call for the first half of the 2024 fiscal year on August 13, 2......
Themefolio
Profiler
Peergroup
© EQS Newswire
07.08.2024
FYB
LISTED
XETR
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
News Preview
Pressemitteilung // 07. August 2024
Formycon lädt zur Telefonkonferenz zu den Ergebnissen des ersten Halbjahres 2024 ein und gibt Teilnahme an internationalen Investorenkonferenzen bekannt
Planegg-Martinsried –Die Formycon AG (FWB: FYB, „Formycon“) hat heute Details zur Telefonkonferenz zur Veröffentlichung der Ergebnisse des ersten Geschäfts......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
EVT
LISTED
XETR
Evotec provides guidance update
News Preview
Navigating through a challenging H1 2024: Unsatisfying revenue dynamics in Shared R&D; Just – Evotec Biologics with mid double-digit revenue growth versus strong comparable basis
Adjusted EBITDA impacted by high fixed cost base in Shared R&D and ramp-up costs for J.POD Toulouse, France
Further strengthened sales order book i......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
EVT
LISTED
XETR
Evotec gibt Prognose Update bekannt
News Preview
Navigieren durch ein herausforderndes H1 2024: Unbefriedigende Umsatzdynamik im Bereich Shared R&D; Just – Evotec Biologics mit mittlerem zweistelligem Umsatzwachstum gegenüber starkem vergleichbarem Vorjahreszeitraum
Bereinigtes EBITDA durch hohe Fixkostenbasis im Bereich Shared R&D und Aufbaukosten für J.POD Toulouse, Frankrei......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
EVT
LISTED
XETR
Evotec SE provides guidance update
News Preview
Ad hoc: Evotec SE provides guidance update
Hamburg, Germany, – Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) announces that it has refined its guidance for the fiscal year 2024.
The Company expects Group revenues in the range of € 790 – 820 m (low to mid-single-digit percent......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
EVT
LISTED
XETR
Evotec SE veröffentlicht Prognose Update
News Preview
Ad hoc: Evotec SE veröffentlicht Prognose Update
Hamburg– Evotec SE (Frankfurter Wertpapierbörse: EVT, Prime Standard, ISIN: DE 000 566480 9, WKN 566480; NASDAQ: EVO) gibt bekannt, dass das Unternehmen seine Prognose für das Geschäftsjahr 2024 angepasst hat.
Das Unternehmen erwartet einen Konzernumsatz von 790 – 820 Mio. € (niedriges bis mittlere......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
FYB
LISTED
XETR
Formycon AG increases its outlook for the 2024 fiscal year
News Preview
Disclosure of inside information according to Article 17 of the Regulation (EU) No 596/2014
Formycon AG increases its outlook for the 2024 fiscal year
Planegg-Martinsried, Germany, August 06, 2024 – Formycon AG (ISIN: DE000A1EWVY8 / WKN: A1EWVY) (“Company”) has today decided, based on the preliminary half-year figures, to raise its guidance for t......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
FYB
LISTED
XETR
Formycon AG hebt Prognose für das Geschäftsjahr 2024 an
News Preview
Veröffentlichung von Insiderinformationen nach Artikel 17 der Verordnung (EU) Nr. 596/2014
Formycon AG hebt Prognose für das Geschäftsjahr 2024 an
Planegg-Martinsried, Deutschland, 06. August 2024 – Die Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) ("Gesellschaft") hat heute auf Basis der vorläufigen Halbjahreszahlen entschieden, die Prognose für......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
AFX
LISTED
XETR
Carl Zeiss Meditec schließt die ersten neun Monate 2023/24 mit leicht rückläufigem Umsatz ab
News Preview
Carl Zeiss Meditec schließt die ersten neun Monate 2023/24 mit leicht rückläufigem Umsatz ab
Restriktives Investitionsklima und niedrige Verbraucherstimmung belasten Umsatz- und Ertragsentwicklung
JENA, 6. August 2024
Carl Zeiss Meditec erreichte in den ersten neun Monaten des Geschäftsjahres 2023/24 einen Umsatz von rund 1.486,5 Millionen......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
AFX
LISTED
XETR
Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue
News Preview
Carl Zeiss Meditec closes first nine months of 2023/24 with slight decline in revenue
Restrictive investment climate and low consumer confidence impact revenue and earnings performance
JENA, 6 August 2024
Carl Zeiss Meditec generated revenue of around €1,486.5m in the first nine months of fiscal year 2023/24 (prior year: €1,509.6m) corresp......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
SOON
LISTED
SIX
Sonova announces two new hearing aid platforms, including the first hearing aid with real-time AI to address most pressing need in hearing loss
News Preview
Sonova Holding AG
/ Key word(s): Market launch/Product Launch
Sonova announces two new hearing aid platforms, including the first hearing aid with real-time AI to address most pressing need in hearing loss
06.08.2024 / 06:55 CET/CEST
Media Release
Understanding speech in background noise (‘speech-in-noise’ problem) is t......
Themefolio
Profiler
Peergroup
© EQS Newswire
06.08.2024
SOON
LISTED
SIX
Sonova kündigt zwei neue Hörgeräte-Plattformen an, einschliesslich des ersten Hörgeräts mit Echtzeit-KI, um das schwerwiegendste Bedürfnis bei Hörverlust abzudecken
News Preview
Sonova Holding AG
/ Schlagwort(e): Markteinführung/Produkteinführung
Sonova kündigt zwei neue Hörgeräte-Plattformen an, einschliesslich des ersten Hörgeräts mit Echtzeit-KI, um das schwerwiegendste Bedürfnis bei Hörverlust abzudecken
06.08.2024 / 06:55 CET/CEST
Medienmitteilung
Das Sprachverstehen im Lärm (Speech-in-Noi......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
ANAB
LISTED
NASDAQ
Anaptys Announces Second Quarter 2024 Financial Results and Provides Business Update
News Preview
SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial results for the second quarter ended June 30, 2024 and provided a business update....
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2024
EUZ
LISTED
XETR
Eckert & Ziegler extends GalliaPharm® availability to the entire European Economic Area
News Preview
August 5, 2024 - Berlin - Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) has received approval from the European Commission (EC) for its Ge-68/Ga-68 radionuclide generator GalliaPharm®. The generator was first launched in 2014 and is today approved in 17 European countries and many other key international markets. With the EC approval......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2024
EUZ
LISTED
XETR
Eckert & Ziegler weitet Verfügbarkeit von GalliaPharm® auf den gesamten Europäischen Wirtschaftsraum aus
News Preview
5. August 2024 - Berlin - Die Eckert & Ziegler Radiopharma GmbH (Eckert & Ziegler) hat von der Europäischen Kommission (EK) die Zulassung für ihren Ge-68/Ga-68 Radionuklidgenerator GalliaPharm® erhalten. Der Generator wurde erstmals 2014 auf den Markt gebracht und ist heute in 17 europäischen Ländern und vielen anderen internationalen Schlü......
Themefolio
Profiler
Peergroup
© PR Newswire
05.08.2024
ATNM
LISTED
XASE
Actinium Provides Regulatory Update on Planned BLA Filing and Future Plans for Iomab-B in the U.S.
News Preview
FDA determined that the Phase 3 SIERRA trial is not adequate to support a BLA filing for Iomab-B despite its statistically significant primary endpointAdditional head-to-head randomized clinical trial demonstrating overall survival benefit with Iomab-B is required by FDA to support a BLA filingActinium to request a meeting with the FDA to further...
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2024
ILM1
LISTED
XETR
Medios baut den Bereich „Advanced Therapies“ aus und ernennt Dr. Andreas Schmiede zum Vice President
News Preview
Medios baut den Bereich „Advanced Therapies“ aus und ernennt Dr. Andreas Schmiede zum Vice President
Berlin, 5. August 2024 – Die Medios AG („Medios“), ein führender Anbieter von Specialty Pharma in Europa, verstärkt seine Aktivitäten im Bereich „Advanced Therapies“ und ernennt in diesem Zuge Dr. Andreas Schmiede zum Vice President Advanced Therap......
Themefolio
Profiler
Peergroup
© EQS Newswire
05.08.2024
ILM1
LISTED
XETR
Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President
News Preview
Medios expands „Advanced Therapies“ field and appoints Dr. Andreas Schmiede as Vice President
Berlin, August 5, 2024 – Medios AG (“Medios“), a leading provider of Specialty Pharma in Europe, strengthens its activities in the field of Advanced Therapies and appoints Dr. Andreas Schmiede as Vice President Advanced Therapies. The entry into the Advan......
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
EAPI
LISTED
EURONEXT
EUROAPI - Availability of 2024 Half-Year Financial Report
News Preview
...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
DBV
LISTED
EURONEXT
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024
News Preview
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
MURA
LISTED
NASDAQ
Mural Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News Preview
WALTHAM, Mass. and DUBLIN, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Mural Oncology plc (Nasdaq: MURA), a clinical-stage immuno-oncology company developing novel, investigational engineered cytokine therapies designed to address areas of unmet need for patients with a variety of cancers, today announced that on August 1, the Company granted to one newly...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
OSE
LISTED
EURONEXT
Informations relatives au nombre total de droits de vote et d’actions composant le capital
News Preview
Informations relatives au nombre total de droits de vote et d’actions composant le capital...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
INSP
LISTED
NYSE
Inspire Medical Systems, Inc. Announces FDA Approval of the Inspire V System
News Preview
MINNEAPOLIS, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire), a medical technology company focused on the development and commercialization of innovative, minimally invasive solutions for patients with obstructive sleep apnea (OSA), today announced the FDA approval of the Inspire V therapy system which inclu...
Themefolio
Profiler
Peergroup
© Globe Newswire
02.08.2024
MDGL
LISTED
NASDAQ
Madrigal Pharmaceuticals Appoints Shannon Kelley as General Counsel
News Preview
CONSHOHOCKEN, Pa., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH), today announced the appointment of Shannon Kelley as General Counsel, effective August 5, 2024....
Themefolio
Profiler
Peergroup
© PR Newswire
01.08.2024
ATNM
LISTED
XASE
Actinium Expands Patent Coverage Over Iomab-ACT, its Next-Generation Targeted Radiotherapy Conditioning Agent, for Gene Edited Stem Cell-Based Therapies for Non-Malignant Indications
News Preview
- Newly issued U.S. patent augments Actinium's existing composition of matter patent coverage over Iomab-B and Iomab-ACT targeted radiotherapy conditioning programs
- Pertains to the use of Iomab-ACT with genetically engineered hematopoietic stem cells for treating non-malignant diseases including sickle cell disease, severe combined...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
IMCR
LISTED
NASDAQ
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024
News Preview
Immunocore to report second quarter 2024 financial results and host call on August 8, 2024...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
TFX
LISTED
NYSE
Teleflex Announces Quarterly Dividend
News Preview
WAYNE, Pa., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 16, 2024, to shareholders of record at the close of business on August 15, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
01.08.2024
TIL
LISTED
NASDAQ
Instil Bio and ImmuneOnco Announce License and Collaboration Agreement for Development of IMM2510, a Potentially Best-in-Class PD-L1xVEGF Bispecific Antibody, and IMM27M, a Novel Next-Generation Anti-CTLA-4 Antibody
News Preview
DALLAS and SHANGHAI, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”) and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced a definitive agreement pursuant to which Instil is in-licensing ex-China development and commercial rights to ImmueOnco’s proprietary PD-L1xVEGF bispe...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
